Aleksandra Maria Górska

Dr. Aleksandra Maria Górska

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in The Lancet Haematology
Verified
Journal Article
Closed access
WSWolfgang R. Sperr
Wolfgang R. Sperr
MKMichael Kundi
Michael Kundi
IAIvan Alvarez-Twose
Ivan Alvarez-Twose
BABjorn van Anrooij
Bjorn van Anrooij
JEJoanna N G Oude Elberink
Joanna N G Oude Elberink
Peter ValentPeter Valent
Peter Valent

Verified
Journal Article
Open access
PDF file
Peter ValentPeter Valent
Peter Valent
CACem Akin
Cem Akin
Bogusław NedoszytkoBogusław Nedoszytko
Bogusław Nedoszytko
PBPatrizia Bonadonna
Patrizia Bonadonna
KHKarin Hartmann
Karin Hartmann
DMDean D. Metcalfe
Dean D. Metcalfe
Mast cell activation (MCA) is seen in a variety of clinical contexts and pathologies, including IgE-dependent allergic inflammation, other immunologic and inflammatory reactions, primary mast cell (MC) disorders, and hereditary alpha tryptasemia (HAT). MCA-related symptoms range from mild to severe to life-threatening. The severity of MCA-related symptoms depends on a number of factors, including genetic predisposition, the number and releasability of MCs, organs affected, and the type and consequences of comorbid conditions. In severe systemic reactions, MCA is demonstrable by a substantial increase of basal serum tryptase levels above the individual’s baseline. When, in addition, the symptoms are recurrent, involve more than one organ system, and are responsive to therapy with MC-stabilizing or mediator-targeting drugs, the consensus criteria for the diagnosis of MCA syndrome (MCAS) are met. Based on the etiology of MCA, patients can further be classified as having i) primary MCAS where KIT-mutated, clonal, MCs are detected; ii) secondary MCAS where an underlying IgE-dependent allergy or other reactive MCA-triggering pathology is found; or iii) idiopathic MCAS, where neither a triggering reactive state nor KIT-mutated MCs are identified. Most severe MCA events occur in combined forms of MCAS, where KIT-mutated MCs, IgE-dependent allergies and sometimes HAT are detected. These patients may suffer from life-threatening anaphylaxis and are candidates for combined treatment with various types of drugs, including IgE-blocking antibodies, anti-mediator-type drugs and MC-targeting therapy. In conclusion, detailed knowledge about the etiology, underlying pathologies and co-morbidities is important to establish the diagnosis and develop an optimal management plan for MCAS, following the principles of personalized medicine.

1 January 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
Peter ValentPeter Valent
Peter Valent
JEJoanna N.G. Oude Elberink
Joanna N.G. Oude Elberink
AGAleksandra Maria Górska
Aleksandra Maria Górska
MLMagdalena Lange
Magdalena Lange
RZRoberta Zanotti
Roberta Zanotti
WSWolfgang R. Sperr
Wolfgang R. Sperr

18 November 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
HKHanneke C. Kluin-Nelemans
Hanneke C. Kluin-Nelemans
ARAndreas Reiter
Andreas Reiter
AIAnja Illerhaus
Anja Illerhaus
BABjorn van Anrooij
Bjorn van Anrooij
KHKarin Hartmann
Karin Hartmann
WSWolfgang R. Sperr
Wolfgang R. Sperr

1 January 2017 in Advances in Dermatology and Allergology
Verified
Journal Article
Open access
Bogusław NedoszytkoBogusław Nedoszytko
Bogusław Nedoszytko
MLMagdalena Lange
Magdalena Lange
MSMalgorzata Sokolowska-Wojdylo
Malgorzata Sokolowska-Wojdylo
JRJoanna Renke
Joanna Renke
Piotr TrzonkowskiPiotr Trzonkowski
Piotr Trzonkowski
Roman J. NowickiRoman J. Nowicki
Roman J. Nowicki
Regulatory FOXP3+ T cells (Tregs) constitute 5% to 10% of T cells in the normal human skin. They play an important role in the induction and maintenance of immunological tolerance. The suppressive effects of these cells are exerted by various mechanisms including the direct cytotoxic effect,...

1 July 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
EAElisabeth Aberer
Elisabeth Aberer
WSWolfgang R. Sperr
Wolfgang R. Sperr
ABAgnes Bretterklieber
Agnes Bretterklieber
AAAlexander Avian
Alexander Avian
EHEmir Hadzijusufovic
Emir Hadzijusufovic
Peter ValentPeter Valent
Peter Valent